- ►chestpubs.org J Ansell, J Hirsh, E Hylek, A Jacobson, M … - Chest, 2008 - chestjournal.chestpubs.org This article concerning the pharmacokinetics and pharmacodynamics of vitamin K
antagonists (VKAs) is part of the American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the ... Cited by 892 - Related articles - BL Direct - All 21 versions
- ►ahajournals.org J Broderick, S Connolly, E Feldmann, D … - Circulation, 2007 - Am Heart Assoc Methods— A formal literature search of Medline was performed through the end
date of August 2006. The results of this search were complemented by additional
articles on related issues known to the writing committee. Data were ... Cited by 216 - Related articles - All 14 versions
- ►akuttjournalen.org [PDF] RP Dutton, M McCunn, M Hyder, M D'Angelo, … - The Journal of Trauma, 2004 - journals.lww.com Introduction: Activated factor VIIa (FVIIa) was developed to treat hemophiliacs
with high-titer antibodies to factor VIII. FVIIa initiates thrombin formation by
binding with exposed tissue factor. Anecdotal reports have described the ... Cited by 198 - Related articles - BL Direct - All 8 versions
- ►critcaremed.com M Levi, M Peters, HR Büller - Critical care medicine, 2005 - journals.lww.com Background: Recombinant activated factor VII (factor VIIa) is a prohemostatic
agent that can be used for patients with complicated coagulation disorders.
Recombinant factor VIIa is, however, increasingly used for several other ... Cited by 196 - Related articles - All 14 versions
- ►bloodjournal.org HR Roberts, DM Monroe, GC White - Blood, 2004 - Am Soc Hematology A clinical trial of the effectiveness of PCCs compared with an albumin placebo
was carried out in 1980 and showed that PCCs were significantly more effective
in controlling bleeding in hemophilic patients with inhibitors than an ... Cited by 163 - Related articles - All 5 versions
- ►ahajournals.org SZ Goldhaber, CG Elliott - Circulation, 2003 - Am Heart Assoc Pulmonary embolism (PE) presents with a wide clinical spectrum, from
asymptomatic small PE to life-threatening major PE that causes hypotension and
cardiogenic shock (Table). Traditionally, our risk assessment is done by ... Cited by 132 - Related articles - BL Direct - All 4 versions
WD Freeman, TG Brott, KM Barrett, PR … - Mayo Clinic Proceedings, 2004 - mayoclinicproceedings.com Mayo Clin Proc. • December 2004;79(12):1495-1500 • www.mayo.edu/proceedings ... RECOMBINANT FACTOR VIIa FOR REVERSAL OF ANTICOAGULATION ORIGINAL ARTICLE ... From the Department of Neurology (WDF, TGB, KMB, PRC, JFM), Department ... Cited by 105 - Related articles - View as HTML - BL Direct - All 14 versions
LT Goodnough, DM Lublin, L Zhang, G … - Transfusion, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 102 - Related articles - BL Direct - All 4 versions
- ►critcaremed.org HR Roberts, DM Monroe, MA Escobar - Anesthesiology, 2004 - journals.lww.com * Sarah Graham Kenan Distinguished Professor of Medicine and Pathology, Division
of Hematology/Oncology and the Carolina Cardiovascular Biology Center,
University of North Carolina. † Professor, Department of Medicine, ... Cited by 98 - Related articles - All 7 versions
R Armand, JR Hess - Transfusion Medicine Reviews, 2003 - Elsevier COAGULOPATHY IS probably universal in patients with severe trauma. It is caused
by both coagulation factor and platelet loss associated with vascular disruption
as well as by the intravascular consumption of clotting components ... Cited by 94 - Related articles - BL Direct - All 3 versions
